v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026202520262025
Collaborative arrangement revenue$1,488 $1,373 $3,022 $2,854 
Less:
OCU4002,211 1,998 3,520 3,843 
OCU410 and OCU410ST1,590 1,117 3,966 2,295 
NeoCart196 8 218 5 
COVAXIN3 — 10 — 
Inhaled mucosal vaccine platform49 131 79 319 
OCU20055 151 260 400 
Unallocated costs:
Research and development personnel costs5,150 4,091 10,752 8,106 
Facilities and other support costs842 834 1,675 1,815 
Other594 72 1,465 1,149 
Total research and development10,690 8,402 21,945 17,932 
General and administrative7,242 6,766 15,359 13,218 
Total operating expenses17,932 15,168 37,304 31,150 
Loss from operations(16,444)(13,795)(34,282)(28,296)
Other income (expense):
Interest income395 227 526 571 
Interest expense(4,476)(1,285)(5,796)(2,543)
Loss on extinguishment of debt(2,383)— (2,383)$— 
Change in fair value of derivative liability(1,891)— (1,891)$— 
Other (expense) income, net(78)114 (228)179 
Total other (expense) income(8,433)(944)(9,772)(1,793)
Segment and consolidated net loss$(24,877)$(14,739)$(44,054)$(30,089)